|
1
|
International Agency for Research on
Cancer (IARC): GLOBOCAN 2012: Estimated cancer incidence, mortality
and prevalence worldwide in 2012. (IARC fact sheets). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
Accessed May 27, 2016.
|
|
2
|
Rossari JR, Metzger-Filho O, Paesmans M,
Saini KS, Gennari A, de Azambuja E and Piccart-Gebhart M:
Bevacizumab and breast cancer: A meta-analysis of first-line phase
III studies and a critical reappraisal of available evidence. J
Oncol. 2012:4176732012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shibuya M: Vascular endothelial growth
factor and its receptor system: Physiological functions in
angiogenesis and pathological roles in various diseases. J Biochem.
153:13–19. 2013. View Article : Google Scholar
|
|
4
|
Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu
L, Grzesik DA, Qian H, Xue XN and Pollard JW: Macrophages regulate
the angiogenic switch in a mouse model of breast cancer. Cancer
Res. 66:11238–11246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murakami M, Zheng Y, Hirashima M, Suda T,
Morita Y, Ooehara J, Ema H, Fong GH and Shibuya M: VEGFR1 tyrosine
kinase signaling promotes lymphangiogenesis as well as
angio-genesis indirectly via macrophage recruitment. Arterioscler
Thromb Vasc Biol. 28:658–664. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dales JP, Garcia S, Carpentier S, Andrac
L, Ramuz O, Lavaut MN, Allasia C, Bonnier P and Taranger-Charpin C:
Prediction of metastasis risk (11 year follow-up) using VEGF-R1,
VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905).
Br J Cancer. 90:1216–1221. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mylona E, Alexandrou P, Giannopoulou I,
Liapis G, Sofia M, Keramopoulos A and Nakopoulou L: The prognostic
value of vascular endothelial growth factors (VEGFs)-A and -B and
their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol
Oncol. 104:557–563. 2007. View Article : Google Scholar
|
|
8
|
Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo
M, Shao S, Zuo X and Zhao X: Vascular endothelial growth factor
receptor-1 activation promotes migration and invasion of breast
cancer cells through epithelial-mesenchymal transition. PLoS One.
8:e652172013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schmidt M, Voelker HU, Kapp M, Dietl J and
Kammerer U: Expression of VEGFR-1 (Flt-1) in breast cancer is
associated with VEGF expression and with node-negative tumour
stage. Anticancer Res. 28:1719–1724. 2008.PubMed/NCBI
|
|
10
|
Wülfing P, Kersting C, Buerger H, Mattsson
B, Mesters R, Gustmann C, Hinrichs B, Tio J, Böcker W and Kiesel L:
Expression patterns of angiogenic and lymphangiogenic factors in
ductal breast carcinoma in situ. Br J Cancer. 92:1720–1728. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brown LF, Guidi AJ, Schnitt SJ, Van De
Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K and Dvorak HF:
Vascular stroma formation in carcinoma in situ, invasive carcinoma,
and metastatic carcinoma of the breast. Clin Cancer Res.
5:1041–1056. 1999.PubMed/NCBI
|
|
12
|
Arias-Pulido H, Chaher N, Gong Y, Qualls
C, Vargas J and Royce M: Tumor stromal vascular endothelial growth
factor A is predictive of poor outcome in inflammatory breast
cancer. BMC Cancer. 12:2982012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ruiz C, Seibt S, Al Kuraya K, Siraj AK,
Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska
S, et al: Tissue microarrays for comparing molecular features with
proliferation activity in breast cancer. Int J Cancer.
118:2190–2194. 2006. View Article : Google Scholar
|
|
14
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Kuraya K, Schraml P, Torhorst J, Tapia
C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M,
Köchli O, et al: Prognostic relevance of gene amplifications and
coamplifications in breast cancer. Cancer Res. 64:8534–8540. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hiratsuka S, Minowa O, Kuno J, Noda T and
Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient
for normal development and angiogenesis in mice. Proc Natl Acad Sci
USA. 95:9349–9354. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Linderholm BK, Hellborg H, Johansson U,
Skoog L and Lehtiö J: Vascular endothelial growth factor receptor 2
and downstream p38 mitogen-activated protein kinase are possible
candidate markers of intrinsic resistance to adjuvant endocrine
treatment in steroid receptor positive breast cancer. Breast Cancer
Res Treat. 125:457–465. 2011. View Article : Google Scholar
|
|
18
|
Jin J, Yuan F, Shen MQ, Feng YF and He QL:
Vascular endothelial growth factor regulates primate
choroid-retinal endothelial cell proliferation and tube formation
through PI3K/Akt and MEK/ERK dependent signaling. Mol Cell Biochem.
381:267–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paradiso A, Mangia A, Chiriatti A, Tommasi
S, Zito A, Latorre A, Schittulli F and Lorusso V: Biomarkers
predictive for clinical efficacy of taxol-based chemotherapy in
advanced breast cancer. Ann Oncol. 16(Suppl 4): iv14–iv19. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mezquita B, Mezquita J, Pau M and Mezquita
C: A novel intracellular isoform of VEGFR-1 activates Src and
promotes cell invasion in MDA-MB-231 breast cancer cells. J Cell
Biochem. 110:732–742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toi M, Bando H, Ogawa T, Muta M, Hornig C
and Weich HA: Significance of vascular endothelial growth factor
(VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J
Cancer. 98:14–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bando H, Weich HA, Brokelmann M, Horiguchi
S, Funata N, Ogawa T and Toi M: Association between intratumoral
free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in
breast cancer. Br J Cancer. 92:553–561. 2005.PubMed/NCBI
|
|
23
|
Ryden L, Jirström K, Bendahl PO, Fernö M,
Nordenskjöld B, Stål O, Thorstenson S, Jönsson PE and Landberg G:
Tumor-specific expression of vascular endothelial growth factor
receptor 2 but not vascular endothelial growth factor or human
epidermal growth factor receptor 2 is associated with impaired
response to adjuvant tamoxifen in premenopausal breast cancer. J
Clin Oncol. 23:4695–4704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johansson I, Aaltonen KE, Ebbesson A,
Grabau D, Wigerup C, Hedenfalk I and Rydén L: Increased gene copy
number of KIT and VEGFR2 at 4q12 in primary breast cancer is
related to an aggressive phenotype and impaired prognosis. Genes
Chromosomes. Cancer. 51:375–383. 2012.
|
|
25
|
Gray R, Bhattacharya S, Bowden C, Miller K
and Comis RL: Independent review of E2100: a phase III trial of
bevacizumab plus paclitaxel versus paclitaxel in women with
metastatic breast cancer. J Clin Oncol. 27:4966–4972. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miles DW, de Haas SL, Dirix LY, et al:
Biomarker results from the AVADO phase 3 trial of first-line
bevacizumab plus docetaxel for HER2-negative metastatic breast
cancer. Br J Cancer. 108:1052–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Robert NJ, Diéras V, Glaspy J, et al:
RIBBON-1: randomized, double-blind, placebo-controlled, phase III
trial of chemotherapy with or without bevacizumab for first-line
treatment of human epidermal growth factor receptor 2-negative,
locally recurrent or metastatic breast cancer. J Clin Oncol.
29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Camp RL, Charette LA and Rimm DL:
Validation of tissue microarray technology in breast carcinoma. Lab
Invest. 80:1943–1949. 2000. View Article : Google Scholar
|
|
30
|
Zhang D, Salto-Tellez M, Putti TC, Do E
and Koay ES: Reliability of tissue microarrays in detecting protein
expression and gene amplification in breast cancer. Mod Pathol.
79–84. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sauter G: Representativity of TMA Studies.
Methods Mol Biol. 664:27–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Torhorst J, Bucher C, Kononen J, Haas P,
Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, et
al: Tissue microarrays for rapid linking of molecular changes to
clinical endpoints. Am J Pathol. 159:2249–2256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barlund M, Forozan F, Kononen J, Bubendorf
L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, et
al: Detecting activation of ribosomal protein S6 kinase by
complementary DNA and tissue microarray analysis. J Natl Cancer
Inst. 92:1252–1259. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
